Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2023 16:01 ET | Source: Kineta, Inc.

Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in...
April 20, 2023 08:38 ET | Source: Kineta, Inc.

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in...
April 17, 2023 06:30 ET | Source: Kineta, Inc.

Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023

SEATTLE, April 17, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
April 12, 2023 06:30 ET | Source: Kineta, Inc.

Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors

VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 SEATTLE, April 12, 2023 (GLOBE...
April 03, 2023 06:30 ET | Source: Kineta, Inc.

Kineta to Present at 22nd Annual Needham Healthcare Conference

SEATTLE, April 03, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
March 31, 2023 16:01 ET | Source: Kineta, Inc.

Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update

Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by End of 2023 Successfully Completed the Reverse Merger with Nasdaq-listed...
March 22, 2023 06:30 ET | Source: Kineta, Inc.

Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023

SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
March 08, 2023 06:30 ET | Source: Kineta, Inc.

Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference

SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
March 06, 2023 06:30 ET | Source: Kineta, Inc.

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target

SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune...
March 01, 2023 06:30 ET | Source: Kineta, Inc.

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune...